Advancing molecular medicine with new therapeutic compounds
Drugs under development
Allinky’s pipeline includes two new chemical entities (NCEs):
• A MAP Kinase allosteric inhibitor for the treatment of fibrosis and inflammatory diseases.
• An allosteric Ras inhibitor for the treatment of advanced pancreatic, lung, blood and colorectal cancer.